Kairos Pharma heads into its May 13 earnings print with short sellers beating a notable retreat — and the lending market loosening to match.
Short interest has fallen nearly half over the past month. It dropped 27% in a single week to roughly 0.66% of the free float, extending a sharper monthly unwind of 45%. The absolute level is small — around 138,000 shares short — but the speed of the cover is the story. Shorts were running at well above 250,000 shares earlier in April; most of that position has been unwound in under four weeks.
The lending market reflects that retreat. Availability has opened up to around 188% of current short interest, meaning nearly twice the shorted position is still available to borrow. That is a notably loose pool relative to where it was: borrow availability touched just over 50% in mid-April when short interest was closer to its peak. Cost to borrow has also eased, running at roughly 8.3% APR after sitting above 9.5% at the end of March. The combination of wider availability and softer borrow costs confirms this is an orderly unwind, not a squeeze — shorts found exits without having to fight the tape.
The Street still leans bullish, though the coverage base is thin and the analyst data is stale enough to treat cautiously. D. Boral Capital has reiterated a Buy at a $9 target repeatedly through late 2025, and HC Wainwright initiated in April 2025 with a $12 target — both substantially above the current $0.57 price. A gap of that magnitude between price and target almost certainly reflects the clinical binary risks rather than a pure valuation call: Kairos is pre-revenue, reported a net loss of roughly $1.4 million in the quarter to June 2025, and has a market cap of just $12 million. The bull case rests on ENV105's 86% clinical benefit rate and Department of Defense grant funding. The bear case is the straight arithmetic of ongoing losses without a commercial product in sight.
Factor scores add texture. EPS momentum ranks in the 94th percentile over 30 days — a useful signal that estimate revisions have been heading the right direction even from a loss-making base. The short-score rank of 37 and utilization rank of 20 confirm that bears are not crowding this name. What's notable is the short score itself dipped below 49 this week after holding just above 50 for most of April, a modest softening that tracks the SI unwind.
Earnings history offers a mixed reference. The last three confirmed post-announcement moves were all positive — a 2% next-day gain in April, a 5% pop in March, and a 6% lift in November 2025. The exception was a 1.9% decline in mid-November 2025, followed by a five-day slide of nearly 15%. Peers had a split week: GNPX fell 10% while FRMM gained 20%, highlighting how dispersed returns are across this micro-cap biotech cohort. KAPA itself slipped 6.6% on the week against that backdrop.
The May 13 readout is the next concrete event. With short interest now near a multi-month low and borrow conditions loose, the setup heading in is the least crowded it has been all spring — making clinical and pipeline news the primary driver of whatever comes next.
See the live data behind this article on ORTEX.
Open KAPA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
